Oncotarget

Reviews:

LIM kinases: cofilin and beyond

Chloé Prunier, Renaud Prudent, Reuben Kapur, Karin Sadoul and Laurence Lafanechère _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:41749-41763. https://doi.org/10.18632/oncotarget.16978

Metrics: PDF 2516 views  |   HTML 4270 views  |   ?  


Abstract

Chloé Prunier1,2, Renaud Prudent3, Reuben Kapur4, Karin Sadoul1 and Laurence Lafanechère1

1 Institute for Advanced Biosciences, INSERM, CNRS UMR, Université Grenoble Alpes, Grenoble, France

2 Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands

3 Cellipse SAS, MINATEC-BHT A441, Grenoble Cedex, France

4 Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA

Correspondence to:

Laurence Lafanechère, email:

Keywords: LIM kinases, cytoskeleton, microtubules, inhibitors

Received: January 28, 2017 Accepted: March 10, 2017 Published: April 09, 2017

Abstract

LIM kinases are common downstream effectors of several signalization pathways and function as a signaling node that controls cytoskeleton dynamics through the phosphorylation of the cofilin family proteins. These last 10 years, several reports indicate that the functions of LIM kinases are more extended than initially described and, specifically, that LIM kinases also control microtubule dynamics, independently of their regulation of actin microfilament. In this review we analyze the data supporting these conclusions and the possible mechanisms that could be involved in the control of microtubules by LIM kinases. The demonstration that LIM kinases also control microtubule dynamics has pointed to new therapeutic opportunities. Consistently, several new LIM kinase inhibitors have been recently developed. We provide a comprehensive comparison of these inhibitors, of their chemical structure, their specificity, their cellular effects as well as their effects in animal models of various diseases including cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16978